(143 days)
Not Found
Based on the provided text, there is no indication that this device contains an AI model.
The description details a molecular diagnostic test (PCR) that detects specific DNA sequences using primers and fluorescent probes. The Smart Cycler® instrument is described as monitoring fluorescence, interpreting data, and providing a final result. This process is based on established molecular biology techniques and data analysis algorithms, not on artificial intelligence, deep neural networks, or machine learning.
The text explicitly mentions "Mentions AI, DNN, or ML: Not Found", which further supports the conclusion that AI is not a component of this device.
No
Explanation: The device is an in vitro diagnostic test for detecting nasal colonization of MRSA to aid in prevention and control of infections; it is not intended to diagnose or treat MRSA infections.
Yes
The "Intended Use / Indications for Use" section explicitly states that the "IDI-MRSA™ assay is a qualitative in vitro diagnostic test."
No
The device description clearly states it is an "in vitro diagnostic test" that utilizes "PCR reagents," "hybridization probes," and is performed on a "Smart Cycler® instrument." These are all hardware components and chemical reagents, not solely software.
Yes, this device is an IVD (In Vitro Diagnostic).
The "Intended Use / Indications for Use" section explicitly states: "IDI-MRSA™ assay is a qualitative in vitro diagnostic test for the direct detection of nasal colonization by methicillin-resistant Staphylococcus aureus (MRSA)..."
The "Device Description" also begins by stating: "IDI-MRSA™ assay is a qualitative in vitro diagnostic test for the direct detection of nasal colonization by methicillin-resistant Staphylococcus aureus (MRSA)."
These statements clearly identify the device as an in vitro diagnostic test.
N/A
Intended Use / Indications for Use
IDI-MRSA™ assay is a qualitative in vitro diagnostic test for the direct detection of nasal colonization by methicillin-resistant Staphylococcus aureus (MRSA) to aid in the prevention and control of MRSA infections in healthcare settings. The test performed on the Smart Cycler® instrument with a nasal swab specimen from patients at risk for colonization, utilizes polymerase chain reaction (PCR) for the amplification of MRSA DNA and fluorogenic target-specific hybridization probes for the detection of the amplified DNA.
IDI-MRSA is not intended to diagnose MRSA infections nor to guide or monitor treatment for Concomitant cultures are necessary only to recover organisms for MRSA infections. epidemiological typing or for further susceptibility testing.
Product codes (comma separated list FDA assigned to the subject device)
NOX, NQX
Device Description
Not Found
Mentions image processing
No
Mentions AI, DNN, or ML
No
Input Imaging Modality
Not Found
Anatomical Site
Nasal
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Healthcare settings
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
A multi-center study was conducted on 786 nasal swab specimens collected with the Copan Venturi Transystem. The reference method consisted of an initial analysis with the oxacillin screen agar test after selective growth on mannitol salt agar. Specimens negative for MRSA were subjected to an additional analysis consisting of an enrichment step in trypticase soy broth followed by the oxacillin screen agar test. An MRSA positive specimen was defined as a specimen positive for MRSA by either culture technique. An MRSA negative specimen was defined as a specimen negative for MRSA by both culture techniques.
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Clinical performance: A multi-center study was conducted on 786 nasal swab specimens collected with the Copan Venturi Transystem.
Compared to the culture method of reference, the IDI-MRSA™ identified 92.5% of the specimens positive for MRSA by either culture techniques and 96.4% of the specimens negative by both culture techniques.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Sensitivity: 92.5% (n=146) (86.9-96.2%)
Specificity: 96.4% (n=632) (94.6-97.27%)
Negative predictive value: 98.2%
Positive predictive value: 85.4%
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 866.1640 Antimicrobial susceptibility test powder.
(a)
Identification. An antimicrobial susceptibility test powder is a device that consists of an antimicrobial drug powder packaged in vials in specified amounts and intended for use in clinical laboratories for determining in vitro susceptibility of bacterial pathogens to these therapeutic agents. Test results are used to determine the antimicrobial agent of choice in the treatment of bacterial diseases.(b)
Classification. Class II (performance standards).
0
510(k) Summary
IDI-MRSA™ assay Infectio Diagnostic Inc.
March 17, 2004
| Submitted by: | Infectio Diagnostic Inc.
2050, boul. René-Lévesque O, 4ª étaqe
Sainte-Foy, Québec
Canada
G1V 2K8 |
|---------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Contact: | Christian Choquet, PhD. |
| Name of Device: | |
| Trade Name:
Common Name:
Product Code:
Classification Name | IDI-MRSA™ Assay
Test kit for the detection of methicillin-resistant
Staphylococcus aureus
NOX
System, Nucleic Acid Amplification Test, DNA, Methicillin
Resistant Staphylococcus aureus, Direct Specimen |
| Predicate Device: | PBP2' Latex Agglutination Test (Oxoid)
Mueller Hinton Agar with 4% NaCl and 6 μα/ml oxacillin
(Remel) |
| Device Description: | |
Intended Use:
IDI-MRSA™ assay is a qualitative in vitro diagnostic test for the direct detection of nasal colonization by methicillin-resistant Staphylococcus aureus (MRSA) to aid in the prevention and control of MRSA infections in healthcare settings. The test performed on the Smart Cycler® instrument with a nasal swab specimen from patients at risk for colonization, utilizes polymerase chain reaction (PCR) for the amplification of MRSA DNA and fluorogenic target-specific hybridization probes for the detection of the amplified DNA.
IDI-MRSA is not intended to diagnose MRSA infections nor to guide or monitor treatment for Concomitant cultures are necessary only to recover organisms for MRSA infections. epidemiological typing or for further susceptibility testing.
Test Description:
A nasal specimen is collected and transported to the laboratory using the Copan Venturi Transystem®. For testing, the swab is placed in sample preparation buffer. The specimen is concentrated and lysed. An aliquot of the lysate is added to PCR reagents which contain the MRSA-specific primers used to amplify the genetic target [a sequence near the insertion site of Staphylococcal Cassette Chromosome mec (SCCmec)], if present. The assay also includes
1
an internal control (IC) used to detect PCR inhibitory specimens and to confirm the integrity of an internal of the PC (C is a DNA fragment of 335-bp including a 277-bp assay reagents in hogative optionnel to targets are detected with hybridization probes labeled sequence fluorophores (rnolecular beacons). For the detection of MRSA amplicons, the with quencher beacon contains the fluorophore 5-carboxyfluorescein (amine reactive ester of molocally beader commonly called FAM) at the 5' end and the non-fluorescent quencher carboxy-liderooooin bonneeriy on the opposite end of the oligonucleotide. For the detection moley daboy onlorido (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) ( fluorescein (TET) at the 5' end and the non-fluorescent quencher moiety DABCYL at the 3' end.
For the recovery of MRSA for epidemiological typing or for further antibiotic susceptibility testing, appropriate culture media can be inoculated during specimen preparation or up to 24 hours after its preparation.
The amount of fluorescence at any given cycle, or following cycling, depends on the amount of specific amplicon present at that time. The Smart Cycler® instrument monitors simultaneously the fluorescence emitted by each beacon, interprets all data and at the end of the cycling program provides a final result. The operation of the Smart Cycler® instrument is based on the proprietary microprocessor-controlled I-CORE® (Intelligent Cooling/Heating Optical Reaction) Each Smart Cycler® processing block contains 16 independently controlled, module. programmable I-Core® modules, each with one reaction site. Thermally optimized proprietary programmales combined with the design of the I-CORE® modules allow very rapid temperature cycling and rapid amplification. Up to 6 Smart Cycler® processing blocks can be daisy-chained together, allowing simultaneous analysis of 96 discrete samples.
Substantial Equivalence:
The Infectio Diagnostic Inc. IDI-MRSA™ assay has been found to be substantially equivalent to the Oxoid PBP2' Latex Agglutination Test (K011710) and to the culture technique consisting of nrimary isolation on mannitol salt agar followed by the oxacillin screen agar [Mueller Hinton Agar supplemented with 4% NaCl and 6 µg/ml oxacillin (Remel, K850291)) for confirmed isolates of S. aureus.
The IDI-MRSA™ assay is conducted directly on nasal swab specimens; determination of methicillin resistance with the PBP2' Latex Agglutination Test and with the oxacillin screen agar test are performed on isolates identified as Staphylococcus aureus. All assays detect MRSA.
The IDI-MRSA™ assay determines the presence of MRSA through PCR amplification of a sequence located at the insertion site of the Staphylococcal Cassette Chromosome mec (SCCmec) and detection of amplified products with fluorogenic target-specific hybridization; PBP2' Test uses latex agglutination for the detection of the PBP2' protein, one of the gene product of the mecA gene; the culture technique uses phenotypic characteristics of colonies.
With IDI-MRSA™ assay, interpretation of results is done automatically by the Smart Cycler® Instrument; with the PBP2' Latex Agglutination Test and the culture technique, results are interpreted visually by the user.
The reported performance of the Oxoid PBP2' Latex Agglutination Test In comparison (% agreement) with the oxacillin screen agar test on presumptive S. aureus isolates is 100% (232/232) for MRSA and 100% (87/87) for MSSA. Clinical performances of the IDI-MRSA™ assay and of the culture technique in a multi-center study are described below.
2
Clinical performance
A multi-center study was conducted on 786 nasal swab specimens collected with the Copan Venturi Transystem. The reference method consisted of an initial analysis with the oxacillia ventuir Transystom. The relective growth on mannitol salt agar. Specimens negative for MRSA screen agar tool an additional analysis consisting of an enrichment step in trypticase soy broth were subjectou to an additional by the oxacillin screen agar test. An MRSA culture-( 1 00) our an in the Revel as a specimen positive for MRSA by either culture technique. An positive specimen was defined as a specimen negative for MRSA by both culture techniques.
Compared to the culture method of reference, the IDI-MRSA™ identified 92.5% of the specimens positive for MRSA by either culture techniques and 96.4% of the specimens negative by both culture techniques (Tables 1 and 2). For the population tested, this results in a negative predictive value of 98.2% and a positive predictive value of 85.4%.
| | TAUTOMOTIVE THE TOUCH ATT
. No . Alliable !! . WAN
· · "AYAYAYAYAYAYAY
MARK CHARLES AND STATE
the first of the manage and considered
Yu"AYAYAYAYAYA
· VATAVAZ · · · · · · ·
.
A Children R.
.
.
.
1 and an in contract
WANT " "
W.
. " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " .
Valla Market Art
1 111/07
· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·
A SERIE . 11 . 18
SALE A.M 48 SUB MANAGER COLORS
ally clientify and the collection
controllers and of the production and and and
STORES CAMAN = 1
- 1 41 21 41 4 1 4 5 4 4 4 4 4 4 4 4 1 4 1 7 1 - 1 7 1 7 1 -
.
8 VARAVAVAVA!! V
. F . 1 . 192 PM IPATIANS
Car Man Carlos Mill College Come Come Come Come Come Come Come Come Come Come Come Come Come Come Come Come Come Come Come Come Come Come Come Come Come Come Come Come Come C
.
.
- 1948-1944 11. 1
.
11 " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " "
. Mar 14 Mark
.
.
.
ATITATATATA | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
"AVAYAYAYA"A"","
. " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " .
Sales Caracter At Allian A "
PAFAVAVAVAVAS:
PAYAYUT
The first of the first of the close of the county of the re
Sales of any and any and the world and
A Corporator
.
TAYAYATAY, YAYA
PAYAVAVAVAVAVAVI
CARD COLLECTION
The can be late the state of the care of the comments of the states of the states of the first and any the first and the first and the first and
.
Children and Children Collection of Children Warrant
.
-> · VAVAVANI · ! · !
.
" WAY
1 60 = 4 6 % =
. FAYN
· ! · ! N *AVAVA"A" | A = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = =
Passional Partier
.
|
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| A
LA CONSULTION COLLEGAL CONTRACT CARAGEMENT CALLEM
.
.
.
September 19, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10,
.
.
1 . 1 . 1 . 6 . 40 . 40 . 1
57 YASARY WATER F
A Comments of the Career of Children
And Antiques Market Company
Carlos Corporation
HAYAYA AS = " A
. And the first be the first of the first of the first of the first of the first of the first of the first of the first of the first of the first of the first and
| . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " . " .
ыныстық айданын айтының өземді басының өзен басының өзен беттеген басы бердетін басының өзен басының өзен | | |
| . AV
1 ST SU F S P S A C U C U C U C U C S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S
Park Control Concession
Carlos Production of Carrier
Carles Production Company Company Company Company Company Company Company Company Company Company Company Company Company Company Company Company Company Company Company Comp
.
.
.
.
.
.
.
Mark and Callery Collection
.
September 1998 - 1998 - 1999 - 1999 - 1999 - 1999 - 1999 - 1999 - 1999 - 1999 - 1999 - 1999 - 1999 - 1999 - 1999 - 1999 - 1999 - 1999 - 1999 - 1999 - 1999 - 1999 - 1999 - 199
CAPS PARTY SEAST .
25.11 25 45 2 . 41 11
.
Book of the county of the first of the first of the first of the first of the first of the first of the first of the first of the first of the first and
.
-
-
- 2014 11. 11.
.
A Callin V & V = "Pay"
Saling Marial
and and in and in the the dest in
- 2014 11. 11.
-
- S SSPS * * * * *
And Supportunities of
.
.
CHAMANAFA PALL F
A For Shopper Line
.
| | | |
|
Carles Concession Company Company Company Company Company Company Company Company Company Company Company Company Company Company Company Company Company Company Company Comp
Land States Canada
14.11.201
TTATAAAAAAAAAAAAA
Number
PATATAL PARTAL
11 4 4 4 4 0 0 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11
A FRANCE PROPERTY
ARAFA IPITE ITE
1 1 2000
.
****************************************************************************************************************************************************************************** | | | |
Table 1. Results obtained with IDI-MRSA™ assay in comparison to the reference method '.
Eight (8) specimens that gave initially unresolved results remained upon retesting with IDI-MRSA™ assay and are not included in the table. All 8 were culture negative.
Fourteen (14) of the 23 culture-negative specimens but IDI-MRSA positive were found to be MRSA culture-positive upon further investigation, resulting in a total of 149 culture-positive and IDI-MRSA positive specimens out of a total of 160 culture positive specimens. For 2 of the culture-positive specimens but IDI-MRSA negative, none of the isolates that exhibited methicillin resistance on oxacillin agar plates could be shown to carry the mecA gene when tested with the mecA-specific PCR assay described by Martineau et al.1
- Table 2. Performance of IDI-MRSA™ assay obtained by the investigational sites when compared to the reference method
| | Sensitivity
(95% CI) | Specificity
(95% CI) | No. of unresolved
specimens | Invalid/ total no.
of runs |
|--------|-------------------------------|--------------------------------|--------------------------------|-------------------------------|
| Site 1 | 86.8% (n=38)
(71.9-95.6%) | 99.6% (n=261)
(97.9-100%) | 6 | 0/26 |
| Site 2 | 100% (n=30)
(88.4-100%) | 98.0% (n=102)
(93.1-99.8%) | 16 | 0/21 |
| Site 3 | 89.3% (n=28)
(71.8-97.7%) | 90.8% (n=119)
(84.1-95.3%) | 11 | 1/15 |
| Site 4 | 94.0% (n=50)
(83.5-98.7%) | 94.0% (n=150)
(88.9-97.2%) | 2 | 2/27 |
| Total | 92.5% (n=146)
(86.9-96.2%) | 96.4% (n=632)
(94.6-97.27%) | 35 | 3/89 |
Binomial 95% confidence intervals.
All specimens were unresolved due to failed internal controls indicative of inhibition or reagent failure. Twenty-2 seven (27) of the 35 were resplved upon re-testing.
SCCmec typing of MRSA culture-positive s pecimens a ccording to Oliviera and de Lencastre® revealed specimens of types I, II and IV. There were no SCCmec type III specimens isolated
3
from the study. However, in a separate study, reference strains and other clinical isolates of all SCCmec types were tested and detected with IDI-MRSA™ assay.
Performances obtained by the investigational sites for IDI-MRSA, and the individual culture techniques as compared to the culture reference method (both culture techniques) are presented in Tables 3 and 4.
| method. | ||||
|---|---|---|---|---|
| Site | MRSA prevalence1 | Sensitivity (95% CI)2 | ||
| IDI-MRSATM | OxaMSA3 | OxaTSB4 | ||
| Site 1 | 12.7% (38/300) | 86.8% | ||
| (71.9-95.6%) | 81.6% | |||
| (65.7-92.3%) | ND | |||
| Site 2 | 21.7% (30/138) | 100% | ||
| (88.4-100%) | 93.3% | |||
| (77.9-99.2%) | ND | |||
| Site 3 | 18.9% (28/148) | 89.3% | ||
| (71.8-97.7%) | 64.3% | |||
| (44.1-81.4%) | ND | |||
| Site 4 | 25.0% (50/200) | 94.0% | ||
| (83.5-98.7%) | 80.0% | |||
| (66.3-90.0%) | 78.0% | |||
| (64.0-88.5%) | ||||
| Total | 18.6% (146/786) | 92.5% | ||
| (86.9-96.2%) | 80.1% | |||
| (72.7-86.3%) | ND |
| Table 3. Results obtained for IDI-MRSA™ assay and each culture screening | |
|---|---|
| technique with :specimens positive for MRSA by the culture reference | |
| method. |
Determined from results obtained with the culture reference method (combination of OxaMSA and OxaTSB)
2 Binomial 95% confidence intervals.
3 Oxacillin screen agar test after selective growth on MSA.
4 Oxacillin screen agar test after enrichment in TSB with 6.5% NaCl. Site 4 tested all specimens with both culture techniques while the remaining sites tested only specimens negative with the OxaMSA culture method.
Table 4. Results obtained for IDI-MRSA™ assay and each culture screening technique with specimens negative for MRSA by the culture reference method.
| Site | MSSA1 | Specificity (95% CI)2 | ||
|---|---|---|---|---|
| IDI-MRSATM | OxaMSA3 | OxaTSB4 | ||
| Site 1 | 73/262 | 99.6% | ||
| (97.9-100%) | 100% | |||
| (98.6-100%) | ND | |||
| Site 2 | 25/108 | 98.0% | ||
| (93.2-99.8%) | 100% | |||
| (96.4-100%) | ND | |||
| Site 3 | 24/120 | 90.8% | ||
| (84.1-95.3%) | 100% | |||
| (96.9-100%) | ND | |||
| Site 4 | 16/150 | 94.0% | ||
| (88.9-97.2%) | 100% | |||
| (97.6-100%) | 100% | |||
| (97.6-100%) | ||||
| Total | 138/640 | 96.4% | ||
| (94.6-97.7%) | 100% | |||
| (99.4-100%) | ND |
Number of MSSA in total MRSA culture-negative population
2 Binomial 95% confidence intervals.
3 Oxacillin screen agar test after selective growth on MSA
4 Oxacillin screen agar test after enrichment in TSB with 6.5% NaCl. Site 4 tested all specimens with both oxamin obroom ager loor answer sites tested only specimens negative with the OxaMSA culture method.
As indicated in Table 4, 138 specimens analyzed with culture techniques were deemed by investigational sites to contain methicillin-sensitive S. aureus . Seven (7) yielded positive results with IDI-MRSA™ assay. Upon further investigation with more enhanced culture techniques, 4 were shown to actually contain MRSA
4
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/4/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized eagle with three lines forming its body and wings. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" is arranged in a circular fashion around the eagle.
Public Health Service
MAR 1 8 2004
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
Christian Choquet, Ph.D. VP, Regulatory Affairs and Quality Assurancce Infectio Diagnostic (I.D.I.), Inc. 2050, boul. René-Lévesque O, 4€ étage Sainte-Foy, Québec Canada G1V 2K8
Re: K033415
Trade/Device Name: IDI-MRSA"M Assay Regulation Number: 21 CFR 866.1640 Regulation Name: Antimicrobial susceptibility test powder Regulatory Class: Class II Product Code: NQX Dated: February 16, 2004 Received: February 18, 2004
Dear Dr. Choquet:
We have reviewed your Section 510(k) premarket notification of intent to market the device w o nave a so row and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate for ass suated in the May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The I ou may a controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it r your device to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA be found in The 2017 - 11:10 and our cerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean I lease of actived that i Driver ination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must or uny I edetail the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).
5
Page 2
This letter will allow you to begin marketing your device as described in your Section 510(k) remarket notification. The FDA finding of substantial equivalence of your device to a legally presided predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 594-3084. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.
Sincerely yours,
Saartys
Sally A. Hojvat, M.Sc., Ph.D. Director Division of Microbiology Devices Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
6
Indications for Use
510(k) Number (if known): __K033415
Device Name: IDI-MRSA™
Indications For Use:
IDI-MRSA™ assay is a qualitative in vitro diagnostic test for the direct detection of nasal colonization by methicillin-resistant Staphylococcus aureus (MRSA) to aid in the prevention and colonization by metholim roclotings. The test performed on the Smart Cycler® instrument with a nasal swab specimen from patients at risk for colonization, utilizes Instrument with a hadd ones of other amplification of MRSA DNA and fluorogenic targetspecific hybridization probes for the detection of the amplified DNA.
IDI-MRSA™ assay is not intended to diagnose MRSA infections nor to guide or monitor IDPM On - assay le necessary le necessary only to recover organisms for epidemiological typing or for further susceptibility testing.
Prescription Use X (Part 21 CFR 801 Subpart D) AND/OR
Over-The-Counter Use (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)
Division Sign-Off
Office of In Vitro Diagnostic Device Evaluation and Safety
KO 33415 510(k)___
Page 1 of